Over-expression of mps-1 gene or its gene product(s) results in reduction in size of a variety of malignancies -> Monitor Keywords
Fresh Patents
Monitor Patents Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents Browse Locations
site info Site News  |  monitor Monitor Keywords  |  monitor archive Monitor Archive  |  organizer Organizer  |  account info Account Info  |  
10/29/09 - USPTO Class 514 |  1 views | #20090270321 | Prev - Next | About this Page  514 rss/xml feed  monitor keywords

Over-expression of mps-1 gene or its gene product(s) results in reduction in size of a variety of malignancies

USPTO Application #: 20090270321
Title: Over-expression of mps-1 gene or its gene product(s) results in reduction in size of a variety of malignancies
Abstract: Elevation of MPS-1 in HNSCC samples and its structure/function as a ribosomal ZFP have led us to conclude that MPS-1 might be a subject of interest for malignant tumor therapy. Our data reveal that enhanced expression of MPS-1 protein can strongly suppress tumor cell proliferation. MPS-1 and significantly inhibits tumor growth both in vitro and in vivo in 3 distinct malignant cell lines. We have concluded that over-expression of MPS-1 might be used therapeutically in the treatment of some malignancies. Metallopanstimulin-1 (MPS-1) is a multifunctional ribosomal protein. MPS-1 is a 10 kD zinc finger protein (ZFP) that is present in all tissues and expressed in increased quantities in a wide variety of proliferating tissues and malignancies. The ribosome is a ribonucleoprotein complex of ribosomal RNAs (rRNA) and proteins (r-protein). Conventionally, r-proteins are thought to be responsible for new protein synthesis, but emerging evidence has shown activity exists beyond this. Some extra-ribosomal functions of r-proteins have been observed in close relation to cancer pathology. MPS-1 is over-expressed in the serum and tissue of dozens of malignancies. However, it is unknown whether the enhanced expression of MPS-1 is the cause or result of tumor development and progression. Our preliminary observations show increased MPS-1 decreases paxillin. Recently, paxillin was found to have an important role in regulating both normal and tumor cell proliferation. (end of abstract)



Agent: Brendan C. Stack, Jr., Md - Roland, AR, US
Inventors: Brendan Curran Stack, JR., Brendan Curran Stack, JR., Yuemeng Dai, Yuemeng Dai
USPTO Applicaton #: 20090270321 - Class: 514 12 (USPTO)

Over-expression of mps-1 gene or its gene product(s) results in reduction in size of a variety of malignancies description/claims


The Patent Description & Claims data below is from USPTO Patent Application 20090270321, Over-expression of mps-1 gene or its gene product(s) results in reduction in size of a variety of malignancies.

Brief Patent Description - Full Patent Description - Patent Application Claims
  monitor keywords STATEMENT OF GOVERNMENTAL INTEREST

None

BACKGROUND OF THE INVENTION

Metallopanstimulin-1 (MPS-1) is the multifunctional ribosomal protein RPS27, a component of the 40S ribosomal subunit, and it contains a zinc finger domain of the C4 type. MPS-1 was discovered by Fernandez-Pol from a cDNA library of a human mammary carcinoma cell line (MDA-468), stimulated by the growth factors TGF-β1 and EGF in the presence of cyclohexamide (DNA vector with isolated cDNA gene encoding metallopanstimulin, U.S. Pat. No. 5,243,041, Fernandez-Pol, Sep. 7, 1993). MPS-1 has been found highly expressed in a number of cancers, including HNSCC, (FIG. 1). MPS-1 is a 9.5 kD, 81 amino acid residue polypeptide present at low levels in all tissues and expressed in large quantities in cancers. MPS-1 distributes not only in the cytosol, but also in the nuclei. When MPS is over-expressed, it is either secreted or passively released down a concentration gradient into the extra-cellular space. However, little is known about the role of MPS-1 in regulating cancer cell behavior. MPS-1 is a zinc finger protein (ZFP). ZFPs have been described as “the next targets for anti-viral therapy” (NIH Federal Register 1995; 60; 154:40844-6, August 10).

Reported functions of zinc finger proteins include:

    • 1. Protein synthesis.
    • 2. Viral infections.
    • 3. DNA binding.
    • 4. Steroid binding.
    • 5. RNA binding.
    • 6. Internal reservoir or buffer of zinc and other divalent cations (Cu, Fe, Mg, Mn, etc.).
    • 7. Many other functions have been ascribed to ZFPs that suggest a large and varied role in cellular biochemistry.

The ribosome is a ribonucleoprotein complex of ribosomal RNA (rRNA) and ribosomal protein (r-protein). The eukaryotic ribosome is composed of four rRNAs and about 80 r-proteins. Conventionally, the r-proteins are thought to be responsible for new protein synthesis, but emerging evidence has shown that r-proteins possess many other essential “extra-ribosomal functions”. In Drosophila, r-protein S3 (rpS3) was found to have DNase activity that specifically cleaves DNA containing an apurinic/apyrimidinic (AP) site via a β-elimination reaction, suggesting that rpS3 has a role in DNA repair. Drosophila rpS3 also contains DNA deoxyribophospho diesterase (dRpase) activity and plays an important role in the repair of oxidative and ionizing radiation-induced DNA damage. Moreover, rpS3 can induce mouse plasmacytoma MPC-11 B-cell apoptosis by activating caspase-8/caspase-3. Other research groups have shown that several other r-proteins, such as S29, S27L, S13, and L3, have functions of either promoting or suppressing apoptosis. The r-proteins also have development and proliferation regulation functions. For example, over-expression of rpS19 improves erythroid development and increases the number of erythroid colonies in rpS19-deficient Diamond Blackfan anemia.

It has been long recognized that many r-proteins are over-expressed in various cancer cell lines and primary tumors, but it is not known whether the over-expression of certain r-proteins is a cause of tumor development or a response to rapid cancer cell proliferation. Previous studies have demonstrated that MPS-1 protein is highly expressed in various types of tumors, and higher levels of MPS-1 are related to advanced cancer stage. Therefore, MPS-1 was thought to be involved in tumorigenesis. However, our current data support the notion that high level MPS-1 does not stimulate HNSCC tumor growth, but inhibits tumor growth.

Some extra-ribosomal functions of r-proteins have been observed in close relation to oncogenesis. Naora et al reported that enhancement of RPS3a expression induced transformation of NIH 3T3 cells and formation of tumors in nude mice. In addition, more r-proteins are elevated in various types of cancers, such as over-expression of RPS27a in colorectal carcinoma; enhanced expression of r-proteins S8, L12, L23a, L27 and L30 in hepatocellular carcinoma; and increased expression of RPL19 in prostate cancer. In our previous studies, we found that MPS-1, encoded by a TGF-β inducible gene, is over-expressed in HNSCC and that greater expression of MPS-1 in circulation is related to increased tumor burden

High levels of MPS-1 have also been observed in other various types of human cancers including prostate, colon, liver, breast, and gastric. However, it is not clear whether the MPS-1 at high levels alters tumor cell proliferation and tumor growth.



Continue reading about Over-expression of mps-1 gene or its gene product(s) results in reduction in size of a variety of malignancies...
Full patent description for Over-expression of mps-1 gene or its gene product(s) results in reduction in size of a variety of malignancies

Brief Patent Description - Full Patent Description - Patent Application Claims

Click on the above for other options relating to this Over-expression of mps-1 gene or its gene product(s) results in reduction in size of a variety of malignancies patent application.

Patent Applications in related categories:

20090298774 - Bifunctional molecules for inhibiting hiv entry - Disclosed herein are bifunctional molecules which inhibit HIV entry into the target cell. Also disclosed are novel anti-HIV therapeutics for treatment of patients infected by HIV, including non-B and multi-drug resistant strains. ...

20090298759 - C-reactive protein and its use to treat systemic lupus erythematosus and related conditions - The present invention relates to the use of C-reactive protein, its mutants, metabolites and polypeptides and related compounds thereof for the treatment of various disease states and conditions associated with systemic lupus erythematosus (SLE), including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions ...

20090298769 - Compounds and methods of modulating angiogenesis - A method of modulating angiogenesis in a tissue comprises administering to the tissue a therapeutically effective amount of an agent that modulates complex formation of αvβ3 integrin and VEGFR2. ...

20090298762 - Conjugates of biologically active proteins having a modified in vivo half-life - Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the ...

20090298766 - Detection and treatment of cancers - The present invention relates to methods and compositions for the detection and treatment of melanoma and skin cancers. More particularly, the invention discloses that BCSC-1 expression is altered in melanoma and skin cancer cells, allowing the design of effective detection methods and kits for such conditions. The invention also shows ...

20090298767 - Formulation comprising whey protein and hydrolysates for improving muscle recovery - The present invention relates to a formulation comprising whey protein or a hydrolysate of whey protein, which formulation is capable of inhibiting the expression of TNFα in lipopolysaccharide-stimulated macrophages in vitro. Also provided are uses of the formulation for attenuating a reduction in muscle function which results from muscle damage ...

20090298756 - Functions and uses of gpr39 gene in mammalian central nervous system - The present invention provides mammalian GPR39 gene, its coded products, and the uses in regulating appetite and pain sensitivity. A pharmaceutical composition and a health product comprising GPR39 protein are also provided. The health product and the pharmaceutical composition for suppressing appetite or decreasing pain sensitivity comprise a safe and ...

20090298764 - Gene and pathway and their use in methods and compositions for predicting onset or progression of autoimmune and/or autoinflammatory diseases - Embodiments of the present invention concern methods, compositions and uses thereof, relating to at least one of vitiligo, or vitiligo-associated autoimmune/autoinflammatory disease (VAAAD). In particular embodiments, genetic variations in the NALP1 gene are of use to detect, diagnose, predict the risk of or treat at least one of vitiligo or ...

20090298754 - Hai-1 and hai-2 in cancer therapy - The invention relates to a novel therapeutic composition for treating cancer, and particularly prostrate and breast cancer, the composition comprises mixture of two hepatocyte growth factor activator inhibitors HAI-1 and HAI-2. ...

20090298770 - Mammalian relaxin receptors - High affinity relaxin receptors, polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided. These proteins, herein termed LGR7 and LGR8, are orphan leucine-repeat-containing, G protein-coupled receptors. These receptors have a wide and a unique tissue expression pattern. The receptors, particularly soluble fragments thereof, are useful ...

20090298765 - Metastin derivatives and use thereof - The invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, etc.). By modifying the constituent amino acids of metastin with specific modifying groups, metastin derivatives having more improved blood stability, etc. than native metastin and showing excellent cancer metastasis suppressing ...

20090298775 - Method of measuring neprilysin activity - The present invention provides a method of measuring the activity of neprilysin, etc. More specifically, the present invention provides a method of measuring the activity of neprilysin in nerve cells; a method of screening a protein, a peptide or a compound enhancing the activity or expression of neprilysin in nerve ...

20090298773 - Methods of producing functional miso - According to the present invention a miso with good flavor and a processed food containing the miso are provided, wherein the miso and the food are expected to have an repressing effect on an increase in blood pressure or hypotensive effect by continually taking the miso or food for routinely ...

20090298761 - Methods of treating cartilage defects using a soluble morphogenic protein complex - The present invention provides methods of repairing and regenerating cartilage tissue using a soluble morphogenic protein complex comprising (a) a morphogenic protein; and (b) a morphogenic protein pro region isolated from a morphogenic protein, or a conservative substitution variant or a fragment of said pro region, wherein said pro region ...

20090298760 - Modified coagulation factor viia with extended half-life - The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked ...

20090298755 - Novel chimeric analgesic peptides - The present invention provides a novel chimeric peptide containing an opioid peptide moiety and a nociceptive peptide moiety for producing analgesia. ...

20090298757 - Oxyntomodulin analogues and their effects on feeding behaviour - Compounds of the invention are novel peptide analogues of oxyntomodulin (oxm) in which one or more amino acids of the oxm sequence have been changed. Changing amino acids 15-24 of oxm to either amino acids 968-977 of the α-latrotoxin peptide (and variations thereof) or amino acids 15-24 of exendin-4 (and ...

20090298763 - Polynucleotides and polypeptide sequences involved in the process of bone remodeling - This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling, variants and derivatives of the polynucleotides and corresponding polypeptides, uses of the polynucleotides, polypeptides, variants and derivatives, and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. ...

20090298777 - Spinal fusion methods and devices - Methods, devices and compositions for fusing adjacent vertebrae, and otherwise localizing bone growth, are provided. In one form of the invention, a method for fusing adjacent vertebrae includes preparing a disc space for receipt of an intervertebral disc implant in an intervertebral disc space between adjacent vertebrae, inserting the implant ...

20090298776 - Spinal fusion methods and devices - Methods, devices and compositions for fusing adjacent vertebrae, and otherwise localizing bone growth, are provided. In one form of the invention, a method for fusing adjacent vertebrae includes preparing a disc space for receipt of an intervertebral disc implant in an interwertebral disc space between adjacent vertebrae, inserting the implant ...

20090298768 - Stable liquid formulation of human growth hormone - Disclosed herein is a stable liquid formulation comprising human growth hormone; L-lysine, L-arginine or polyethylene glycol 300; and poly(oxyethylene) poly(oxypropylene) copolymer, polyethylene glycol-15 polyoxystearate or polyethylene glycol-35 castor oil. ...

20090298772 - Therapeutics to inhibit mll-menin interaction for treating leukemia - Cell permeable peptides derived from MLL that block the interaction of MLL with menin for the treatment of acute mycloid and acute lymphoid leukemia are disclosed. Small molecules interfere with the interaction of MLL with any of its binding partners. ...

20090298758 - Thymosin beta 4 derivatives and use thereof - The present invention relates to thymosin β4 (Tβ4) derivatives, Gly-Tβ4 and Ala-Tβ4. The present invention further relates to a pharmaceutical composition comprising the said Tβ4 derivatives. The present invention also relates to the use of said Tβ4 derivatives in manufacture of a medicament for treatment of skin lesion, heart injury, ...

20090298771 - Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome - This invention relates to the use of secreted SF01-SF13 proteins, to the use of polynucleotides encoding these, and to the use of effectors/modulators thereof in the diagnosis, study, prevention, and treatment of pancreatic diseases (e.g. diabetes mellitus), obesity and/or metabolic syndrome and to the use in regeneration of tissues such ...


###
monitor keywords

How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.  
Start now! - Receive info on patent apps like Over-expression of mps-1 gene or its gene product(s) results in reduction in size of a variety of malignancies or other areas of interest.
###


Previous Patent Application:
Multi-domain amphipathic helical peptides and methods of their use
Next Patent Application:
Pharmaceutical compositions comprising bioelastomer fusion proteins
Industry Class:
Drug, bio-affecting and body treating compositions

###

FreshPatents.com Support
Thank you for viewing the Over-expression of mps-1 gene or its gene product(s) results in reduction in size of a variety of malignancies patent info.
IP-related news and info


Results in 1.95158 seconds


Other interesting Feshpatents.com categories:
Accenture , Agouron Pharmaceuticals , Amgen , AT&T , Bausch & Lomb , Callaway Golf paws
filepatents (1K)

* Protect your Inventions
* US Patent Office filing
patentexpress PATENT INFO